Loading…

Current and Emerging Radiotherapy Options for Uveal Melanoma

What treatment options are there for patients having uveal melanoma? A randomized, prospective, multi-institutional clinical trial (COMS) showed no difference in survival between brachytherapy and enucleation for medium-sized lesions. With the obvious benefit of retaining the eye, brachytherapy has...

Full description

Saved in:

Bibliographic Details
Published in:	Cancers 2024-03, Vol.16 (5), p.1074
Main Authors:	Semeniuk, Oleksii, Yu, Esther, Rivard, Mark J
Format:	Article
Language:	English
Subjects:	Anesthesia Brachytherapy Cancer Cancer therapies Care and treatment Enucleation Glaucoma Hemorrhage Medical prognosis Melanoma Metastasis Mutation Optic nerve Pathogenesis Patients Photons Protons Radiation therapy Radioisotope brachytherapy Radioisotopes Radiosurgery Retinal detachment Review Seeds Tumorigenesis Tumors
Citations:	Items that this one cites
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

cited_by
cites	cdi_FETCH-LOGICAL-c443t-c173ebf5a305dc8128fe184061583d44fcfa6adacb8cad9841a4c79d14dafe983
container_end_page
container_issue	5
container_start_page	1074
container_title	Cancers
container_volume	16
creator	Semeniuk, Oleksii Yu, Esther Rivard, Mark J
description	What treatment options are there for patients having uveal melanoma? A randomized, prospective, multi-institutional clinical trial (COMS) showed no difference in survival between brachytherapy and enucleation for medium-sized lesions. With the obvious benefit of retaining the eye, brachytherapy has flourished and many different approaches have been developed such as low-dose-rate sources using alternate low-energy photon-emitting radionuclides, different plaque designs and seed-loading techniques, high-dose-rate brachytherapy sources and applicators, and low- and high-dose-rate beta-emitting sources and applicators. There also have been developments of other radiation modalities like external-beam radiotherapy using linear accelerators with high-energy photons, particle accelerators for protons, and gamma stereotactic radiosurgery. This article examines the dosimetric properties, targeting capabilities, and outcomes of these approaches. The several modalities examined herein have differing attributes and it may be that no single approach would be considered optimal for all patients and all lesion characteristics.
doi_str_mv	10.3390/cancers16051074
format	article
fullrecord	<record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10931396</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A786429585</galeid><sourcerecordid>A786429585</sourcerecordid><originalsourceid>FETCH-LOGICAL-c443t-c173ebf5a305dc8128fe184061583d44fcfa6adacb8cad9841a4c79d14dafe983</originalsourceid><addsrcrecordid>eNptkc1rHSEUxaU0NCHNursy0E03L9HRUQcKJTzSppASCMla7tPri2FGX3UmkP8-PvIdqgtFf-fouZeQL4wect7TIwvRYi5M0o5RJT6QvZaqdiFlLz6-2u-Sg1JuaB2cMyXVJ7LLtVBccLpHfiznnDFODUTXnIyY1yGumwtwIU3XmGFz15xvppBiaXzKzdUtwtD8xQFiGuEz2fEwFDx4XPfJ1a-Ty-Xp4uz895_l8dnCCsGnhWWK48p3wGnnrGat9si0oJJ1mjshvPUgwYFdaQuu14KBsKp3TDjw2Gu-T34--G7m1YjO1v9mGMwmhxHynUkQzNubGK7NOt0aRnvOeC-rw_dHh5z-zVgmM4Zicag5MM3FtH0nZS2KYhX99g69SXOONd-W6kTLW6lfqDUMaEL0qT5st6bmWGkpKqq7Sh3-h6rT4RhsiuhDPX8jOHoQ2JxKyeifQzJqtk0375peFV9f1-aZf2oxvweZqKfx</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2955423268</pqid></control><display><type>article</type><title>Current and Emerging Radiotherapy Options for Uveal Melanoma</title><source>Open Access: PubMed Central</source><source>ProQuest - Publicly Available Content Database</source><creator>Semeniuk, Oleksii ; Yu, Esther ; Rivard, Mark J</creator><creatorcontrib>Semeniuk, Oleksii ; Yu, Esther ; Rivard, Mark J</creatorcontrib><description>What treatment options are there for patients having uveal melanoma? A randomized, prospective, multi-institutional clinical trial (COMS) showed no difference in survival between brachytherapy and enucleation for medium-sized lesions. With the obvious benefit of retaining the eye, brachytherapy has flourished and many different approaches have been developed such as low-dose-rate sources using alternate low-energy photon-emitting radionuclides, different plaque designs and seed-loading techniques, high-dose-rate brachytherapy sources and applicators, and low- and high-dose-rate beta-emitting sources and applicators. There also have been developments of other radiation modalities like external-beam radiotherapy using linear accelerators with high-energy photons, particle accelerators for protons, and gamma stereotactic radiosurgery. This article examines the dosimetric properties, targeting capabilities, and outcomes of these approaches. The several modalities examined herein have differing attributes and it may be that no single approach would be considered optimal for all patients and all lesion characteristics.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers16051074</identifier><identifier>PMID: 38473430</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Anesthesia ; Brachytherapy ; Cancer ; Cancer therapies ; Care and treatment ; Enucleation ; Glaucoma ; Hemorrhage ; Medical prognosis ; Melanoma ; Metastasis ; Mutation ; Optic nerve ; Pathogenesis ; Patients ; Photons ; Protons ; Radiation therapy ; Radioisotope brachytherapy ; Radioisotopes ; Radiosurgery ; Retinal detachment ; Review ; Seeds ; Tumorigenesis ; Tumors</subject><ispartof>Cancers, 2024-03, Vol.16 (5), p.1074</ispartof><rights>COPYRIGHT 2024 MDPI AG</rights><rights>2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2024 by the authors. 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c443t-c173ebf5a305dc8128fe184061583d44fcfa6adacb8cad9841a4c79d14dafe983</cites><orcidid>0000-0002-5532-6521</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2955423268/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2955423268?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38473430$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Semeniuk, Oleksii</creatorcontrib><creatorcontrib>Yu, Esther</creatorcontrib><creatorcontrib>Rivard, Mark J</creatorcontrib><title>Current and Emerging Radiotherapy Options for Uveal Melanoma</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>What treatment options are there for patients having uveal melanoma? A randomized, prospective, multi-institutional clinical trial (COMS) showed no difference in survival between brachytherapy and enucleation for medium-sized lesions. With the obvious benefit of retaining the eye, brachytherapy has flourished and many different approaches have been developed such as low-dose-rate sources using alternate low-energy photon-emitting radionuclides, different plaque designs and seed-loading techniques, high-dose-rate brachytherapy sources and applicators, and low- and high-dose-rate beta-emitting sources and applicators. There also have been developments of other radiation modalities like external-beam radiotherapy using linear accelerators with high-energy photons, particle accelerators for protons, and gamma stereotactic radiosurgery. This article examines the dosimetric properties, targeting capabilities, and outcomes of these approaches. The several modalities examined herein have differing attributes and it may be that no single approach would be considered optimal for all patients and all lesion characteristics.</description><subject>Anesthesia</subject><subject>Brachytherapy</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Enucleation</subject><subject>Glaucoma</subject><subject>Hemorrhage</subject><subject>Medical prognosis</subject><subject>Melanoma</subject><subject>Metastasis</subject><subject>Mutation</subject><subject>Optic nerve</subject><subject>Pathogenesis</subject><subject>Patients</subject><subject>Photons</subject><subject>Protons</subject><subject>Radiation therapy</subject><subject>Radioisotope brachytherapy</subject><subject>Radioisotopes</subject><subject>Radiosurgery</subject><subject>Retinal detachment</subject><subject>Review</subject><subject>Seeds</subject><subject>Tumorigenesis</subject><subject>Tumors</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNptkc1rHSEUxaU0NCHNursy0E03L9HRUQcKJTzSppASCMla7tPri2FGX3UmkP8-PvIdqgtFf-fouZeQL4wect7TIwvRYi5M0o5RJT6QvZaqdiFlLz6-2u-Sg1JuaB2cMyXVJ7LLtVBccLpHfiznnDFODUTXnIyY1yGumwtwIU3XmGFz15xvppBiaXzKzdUtwtD8xQFiGuEz2fEwFDx4XPfJ1a-Ty-Xp4uz895_l8dnCCsGnhWWK48p3wGnnrGat9si0oJJ1mjshvPUgwYFdaQuu14KBsKp3TDjw2Gu-T34--G7m1YjO1v9mGMwmhxHynUkQzNubGK7NOt0aRnvOeC-rw_dHh5z-zVgmM4Zicag5MM3FtH0nZS2KYhX99g69SXOONd-W6kTLW6lfqDUMaEL0qT5st6bmWGkpKqq7Sh3-h6rT4RhsiuhDPX8jOHoQ2JxKyeifQzJqtk0375peFV9f1-aZf2oxvweZqKfx</recordid><startdate>20240306</startdate><enddate>20240306</enddate><creator>Semeniuk, Oleksii</creator><creator>Yu, Esther</creator><creator>Rivard, Mark J</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-5532-6521</orcidid></search><sort><creationdate>20240306</creationdate><title>Current and Emerging Radiotherapy Options for Uveal Melanoma</title><author>Semeniuk, Oleksii ; Yu, Esther ; Rivard, Mark J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c443t-c173ebf5a305dc8128fe184061583d44fcfa6adacb8cad9841a4c79d14dafe983</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Anesthesia</topic><topic>Brachytherapy</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Enucleation</topic><topic>Glaucoma</topic><topic>Hemorrhage</topic><topic>Medical prognosis</topic><topic>Melanoma</topic><topic>Metastasis</topic><topic>Mutation</topic><topic>Optic nerve</topic><topic>Pathogenesis</topic><topic>Patients</topic><topic>Photons</topic><topic>Protons</topic><topic>Radiation therapy</topic><topic>Radioisotope brachytherapy</topic><topic>Radioisotopes</topic><topic>Radiosurgery</topic><topic>Retinal detachment</topic><topic>Review</topic><topic>Seeds</topic><topic>Tumorigenesis</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Semeniuk, Oleksii</creatorcontrib><creatorcontrib>Yu, Esther</creatorcontrib><creatorcontrib>Rivard, Mark J</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>ProQuest research library</collection><collection>ProQuest Biological Science Journals</collection><collection>Research Library (Corporate)</collection><collection>ProQuest - Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Semeniuk, Oleksii</au><au>Yu, Esther</au><au>Rivard, Mark J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Current and Emerging Radiotherapy Options for Uveal Melanoma</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2024-03-06</date><risdate>2024</risdate><volume>16</volume><issue>5</issue><spage>1074</spage><pages>1074-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>What treatment options are there for patients having uveal melanoma? A randomized, prospective, multi-institutional clinical trial (COMS) showed no difference in survival between brachytherapy and enucleation for medium-sized lesions. With the obvious benefit of retaining the eye, brachytherapy has flourished and many different approaches have been developed such as low-dose-rate sources using alternate low-energy photon-emitting radionuclides, different plaque designs and seed-loading techniques, high-dose-rate brachytherapy sources and applicators, and low- and high-dose-rate beta-emitting sources and applicators. There also have been developments of other radiation modalities like external-beam radiotherapy using linear accelerators with high-energy photons, particle accelerators for protons, and gamma stereotactic radiosurgery. This article examines the dosimetric properties, targeting capabilities, and outcomes of these approaches. The several modalities examined herein have differing attributes and it may be that no single approach would be considered optimal for all patients and all lesion characteristics.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>38473430</pmid><doi>10.3390/cancers16051074</doi><orcidid>https://orcid.org/0000-0002-5532-6521</orcidid><oa>free_for_read</oa></addata></record>
fulltext	fulltext
identifier	ISSN: 2072-6694
ispartof	Cancers, 2024-03, Vol.16 (5), p.1074
issn	2072-6694 2072-6694
language	eng
recordid	cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10931396
source	Open Access: PubMed Central; ProQuest - Publicly Available Content Database
subjects	Anesthesia Brachytherapy Cancer Cancer therapies Care and treatment Enucleation Glaucoma Hemorrhage Medical prognosis Melanoma Metastasis Mutation Optic nerve Pathogenesis Patients Photons Protons Radiation therapy Radioisotope brachytherapy Radioisotopes Radiosurgery Retinal detachment Review Seeds Tumorigenesis Tumors
title	Current and Emerging Radiotherapy Options for Uveal Melanoma
url	http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T08%3A19%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Current%20and%20Emerging%20Radiotherapy%20Options%20for%20Uveal%20Melanoma&rft.jtitle=Cancers&rft.au=Semeniuk,%20Oleksii&rft.date=2024-03-06&rft.volume=16&rft.issue=5&rft.spage=1074&rft.pages=1074-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers16051074&rft_dat=%3Cgale_pubme%3EA786429585%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c443t-c173ebf5a305dc8128fe184061583d44fcfa6adacb8cad9841a4c79d14dafe983%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2955423268&rft_id=info:pmid/38473430&rft_galeid=A786429585&rfr_iscdi=true